Aligos Therapeutics Inc Asset Resilience Ratio
Aligos Therapeutics Inc asset resilience ratio. Aligos Therapeutics Inc (ALGS) has an Asset Resilience Ratio of 38.61% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Aligos Therapeutics Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Aligos Therapeutics Inc (2018–2025)
Asset resilience ratio of Aligos Therapeutics Inc from 2018 to 2025. This chart shows how Aligos Therapeutics Inc's Asset Resilience Ratio has changed over time. Read ALGS liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Aligos Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ALGS total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $24.93 Million | 38.61% |
| Total Liquid Assets | $24.93 Million | 38.61% |
Asset Resilience Insights
- Very High Liquidity: Aligos Therapeutics Inc maintains exceptional liquid asset reserves at 38.61% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Aligos Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Aligos Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Aligos Therapeutics Inc Asset Resilience Ratio by Year (2018–2025)
Aligos Therapeutics Inc asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for Aligos Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 67.25% | $59.54 Million | $88.53 Million | +38.80pp |
| 2024-12-31 | 28.45% | $19.94 Million | $70.09 Million | +28.50pp |
| 2023-12-31 | -0.05% | $-70.00K | $151.53 Million | -30.37pp |
| 2022-12-31 | 30.32% | $44.48 Million | $146.69 Million | +28.66pp |
| 2021-12-31 | 1.66% | $3.92 Million | $235.37 Million | -7.05pp |
| 2020-12-31 | 8.72% | $23.13 Million | $265.30 Million | -24.11pp |
| 2019-12-31 | 32.83% | $48.10 Million | $146.52 Million | -29.20pp |
| 2018-12-31 | 62.02% | $66.82 Million | $107.73 Million | -- |
About Aligos Therapeutics Inc
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifosc… Read more